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ABSTRACT
AN EXPLORATORY STUDY OF THE UTILIZATION OF EVIDENCE-BASED
PHARMACOLOGICAL TREATMENT ON HEART FAILURE PATIENTS IN
MISSISSIPPI AND ITS IMPACT ON READMISSION
by Keri Annalyn Barron
May 2017
The purpose of this study was to explore the relationship of adherence to
evidence-based guidelines for pharmacologic management by select Mississippi hospitals
and their hospital readmission rates. This was an exploratory study with a retrospective
design. This design offered insight into the relationship between readmissions of heart
failure patients and adherence to the national guidelines for the pharmacologic treatment
of heart failure. The study took place in a hospital in the southeastern section of the
United States. Data were collected from a database of patients with heart failure seen
between January 2011 and June 2014.
The unit of analysis for this study was the hospitalizations of the heart failure
patients. The researcher limited the study to the first 30 days of the patient’s index
hospitalization and readmissions included in that period. Patient inclusion criteria for this
study included: 18 years of age and older with a diagnosis of heart failure as identified by
the International Classification of Disease (ICD – 9) Codes for heart failure. A
researcher generated data abstraction tool was used to collect data on the variables of
interest: demographic variables and clinical variables. A total of 31 charts comprised the
sample. The Statistical Package for the Social Science (SPSS) software version 23 was
used to analyze collected data.
ii

The overall findings of this study indicated that patients frequently readmit to the
hospital within 30 days of discharge; however, a relationship was not seen between
evidence-based pharmacological therapy and readmission. The researcher concluded that
this finding was due to the small amount of data for analysis. The results also revealed
that some of the pharmacological classes of medications were not utilized, or insufficient
documentation existed about their use or lack thereof.
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CHAPTER I – STATEMENT OF THE PROBLEM
Heart failure is a disease often associated with undesirable outcomes: a decrease
in health and death. A national health care issue, this disease affects myriad individuals
whose treatment costs often prove staggeringly high (Centers for Disease Control and
Prevention, 2013). During onset of heart failure, the heart loses its capability to supply
the body with an adequate blood supply. As a result, patients lose their ability to engage
in daily functions (American Heart Association, 2015a). By the year 2030, heart failure
will cost the United States an estimated $77.7 billion dollars in direct medical costs
(Heidenreich et al., 2011, p. 935). Hospital costs related to this disease’s management
contribute to a major portion of overall hospital expenses (O’Connell, 2000, p. III-7). A
heart failure hospitalization can cost as much as $25,000 and can rise by hundreds of
dollars with each intervention utilized, such as nursing, pharmacotherapy, and/or medical
procedures (Titler et al., 2008; Wang, Zhang, Ayala, Wall, & Fang, 2010).
The lifetime costs associated with the disease are extreme as well. Heart failure
patients can incur lifetime management costs up to approximately $118,000. Most of
these costs are incurred during patients’ hospital stays. Indeed, hospital costs can reach
approximately $84,000 per patient (Dunlay et al., 2011, p. 68). The average cost of stay
for a heart failure patient readmitted within 30 days of discharge is $13,000 (Qasim &
Andrews, 2012, p. 3). For this reason, the Center for Medicare and other agencies have
instituted policies to restrict payment to healthcare institutions (Medicare.gov, n.d.).
While many evidence-based strategies explore ways to reduce these readmissions,
healthcare facilities disagree about the strategies used to reduce readmissions. Shan,
Finder, Dichoso, and Lewis (2014) reported that even though there are interventions
1

favorable to the reduction of heart failure readmissions, such as the transition of care,
managing medications, discharge planning, and follow-up care, hospitals still have issues
with implementation of interventions or an absence of interventions altogether. As a
result, heart failure readmissions remain unacceptably high. Hospitals must be able to
implement these interventions to reduce heart failure readmissions.
Heart failure affects individuals across all ethnic/racial and age groups. The
numbers of individuals affected by heart failure are in the high millions (National Heart,
Lung, and Blood Institute, 2012, p. 5). African Americans are at the top of the list for the
incidence of heart failure. Hispanics and Caucasians are next, followed by Chinese
Americans (Bahrami et al., 2008, pp. 5-6). Caucasian males are at an increased risk of
developing heart failure relative to African American males due to health-related factors,
such as obesity, high blood pressure, and heart attack (Huffman et al., 2013, p. 1510).
Although Caucasian males experience an increased risk of developing the disease,
African-American males over age 60 suffer increased incidence. This is in part due to
African American males suffering greater risk factors that affect the heart’s blood
vessels, such as hypertension and diabetes (Loehr, Rosamond, Chang, Folsom, &
Chambless, 2008, p. 1019).
In Mississippi, heart failure is a particularly significant issue. While chronic
disease accounted for 41.2% of hospital discharges in Mississippi in 2010, heart failure
was the most prevalent of the top three chronic diseases cited for discharges. The other
two chronic diseases were chronic obstructive pulmonary disease and diabetes mellitus.
These discharges accounted for approximately $289,000,000 in hospital charges (Short,
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2014, p. 9). Vital records between 1999-2010 revealed Jackson, Mississippi, to have the
most heart failure-related deaths (Snyder et al., 2014, p. 5).
Heart Failure Readmissions
Readmissions of discharged patients affect all healthcare institutions in the United
States, as readmissions consistently increase healthcare costs. The Centers for Medicare
and Medicaid Services (CMS) (2014) defines readmissions as “an admission to a
subsection (d) hospital within 30 days of discharge from the same or another subsection
(d) hospital.” Subsection (d) hospitals are Medicare hospitals that receive payment from
the Inpatient Prospective Payment System (IPPS), a system that pays based on a patient’s
diagnosis-related group (DRG) (Centers for Medicare and Medicaid Services, 2016a,
2016b). Despite penalties imposed by CMS, patient readmissions during unacceptable
time periods have not significantly abated in all states. Indeed, Mississippi’s
readmissions remain at unacceptable levels.
CMS monitors the number of readmissions to healthcare institutions yearly across
the U.S. and has determined the national readmission rate for heart failure to be 22%
(Data.medicare.gov, 2015a). In 2011, congestive heart failure was cited as the principal
diagnosis for patient readmissions in the United States. Congestive heart failure
accounted for 134,500 patients’ readmissions within 30 days of their initial hospital
release. Those repeat visits resulted in $1.7 billion dollars in healthcare costs (Hines,
Barrett, Jiang, & Steiner, 2014, p. 3).
While data exist that explicate Mississippi readmissions data, inclusive of hospital
guidelines to reduce heart failure readmissions, comparative data are not available that
inform about how Mississippi hospital medication guidelines compare with national
3

evidence-based practice educational guidelines for reducing heart failure readmissions.
Evidence-based practice is the application of best available researched evidence into
practice (Grimmer, Bialocerkowski, Kumar, & Milanese, 2004, p. 189). Evidence-based
practice guidelines are recommendations supported by research that guide clinicians
during patient care (Graham, Mancher, & Wolman, 2011). McKenna, Ashton, and
Keeney (2004) reported that evidence helps to provide quality health service; however,
barriers prevent the best evidence’s translation to practice. Some of these barriers include
little relevance to utilize research into practice, lack of a facilitator to influence change
and having already to remain aware of current changes in healthcare (p. 186-188).
Several clinical practice guidelines assist in the care of patients with heart failure:
(a) the 2013 American College of Cardiology Foundation/American Heart Association
Guideline for the Management of Heart Failure (ACCF/AHA), (b) the Heart Failure
Society of American Heart Failure Guidelines, and (c) American Heart Association Get
with the Guidelines-Heart Failure (AHA, 2015b; Lidenfeld et al., 2010; Yancy et al.,
2013). The ACCF/AHA guidelines prove the most commonly used out of the three. No
previous studies have compared guidelines for treating heart failure with practices used
by health care professionals for treating heart failure in Mississippi. Also, there is a lack
of comparative data to determine whether a relationship exists between evidence-based
pharmacological treatment and readmissions of patients with heart failure in Mississippi.
Purpose of the Study
The purpose of this study was to explore the relationship of adherence to
evidence-based guidelines for pharmacologic management by select Mississippi hospitals
and their hospital readmission rates, particularly as these factors relate to heart failure.
4

Research Questions
This study’s research sought to determine the relationship between adherence to
pharmacological clinical practice guidelines for heart failure patients and readmissions to
select Mississippi hospitals within 30 days or fewer after discharge.
The following questions guided this study:
1.

To what extent are select Mississippi hospitals adhering to evidence-based
pharmacological management guidelines for management of heart failure?

2.

What is the relationship between adherence to guidelines for pharmacologic
management of heart failure and readmission in Mississippi hospitals?
Theoretical Framework
The care of heart failure patients and reduction of readmissions requires an

ongoing relationship between the healthcare system, healthcare system providers, and
patients who are supported by evidence-based practice. Wagner’s Chronic Care Model
(Wagner, Austin, & Korff, 1996) and the theoretical concepts of Donabedian’s Quality of
Care Framework (Donabedian, Wheeler, & Wyszewianski, 1982) combined to form this
study’s theoretical framework.
The Chronic Care Model is composed of six components that intend to address
inconsistencies that sometimes occur in management of patients with chronic disease.
These components focus on the care received within the hospital, as well care provided in
the community. First, the model examines the healthcare organization and structures
within the organization that impact care provided to chronically ill patients. Inclusive are
the systems used to monitor the care of the patients, the mechanisms physicians use to
guide treatment, and the care the patients receive. Secondly, the model incorporates
5

resources in the community that would encourage self-management (Wagner et al., 2002,
p. 70).
Wagner et al. (1996) conducted a meta-analysis to examine the common
characteristics among programs, randomized controlled studies, and interventions in
other countries that were successful in the management of chronic illness. Wagner et al.
(1996) determined that those programs, studies, and interventions were successful
because they shared common several key factors. They followed plans and protocols, met
the needs of the patients through follow-ups, resources, and the provision of more time if
patients needed it, paid attention to changes in their patients, provided experts available
when needed, and offered necessary information systems (p. 518).
The ACCF and AHA have determined through evidence-based research that their
heart failure guidelines can influence the health status of heart failure patients. The
researcher submits that Wagner’s Chronic Care Model appropriately undergirds this
proposed study based upon the six constructs of the model. These constructs provide a
means for understanding evidence-based guidelines in treating heart failure. Stated
differently, this study encompasses the importance of following plans and protocols as
well as paying attention to patients, promoted via Wagner’s research and the use of
evidence-based research in practice. The utilization of Wagner’s model in the redesign of
healthcare protocols has the potential to lead to lower costs and better well-being for
chronically ill individuals (Coleman, Austin, Brach, & Wagner, 2009).
Donabedian et al. (1982) described a framework that illustrates the importance of
a relationship between the health of the patient, quality of care provided, and the costs
associated with that care. This framework further defines quality care as being the care
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that yields the greatest expected improvement in the patient’s health physically,
physiologically, and psychologically (p. 976). As such, Donabedian et al.’s (1982)
framework fits the present study because quality care for heart failure patients must
incorporate the health of the patient, cost-effective treatments, and quality care. To
provide quality care, the researcher submits that healthcare institutions must incorporate
evidence-based practice measures into patient care.
Donabedian et al.’s (1982) framework is composed of three parts: structure,
process, and outcomes. Structure refers to the setting in which the patient receives care.
The process is the actual care that the patient receives, and the outcome is the result of the
patient’s health status after receiving care (Schroeder et al., 2006). The utilization of
outcome as a measure of quality is an accepted measure in many cultures. Improved
health is always a welcomed outcome, and the outcomes become more consistently valid
because they can be measured repeatedly. Thus outcomes can continually validate
whether healthcare measures are effective (Donabedian, 2005, pp. 693-694). Donabedian
et al.’s (1982) framework fits this study because its constructs guides the researcher’s
understanding of outcomes and how to use readmission outcomes as a means to measure
evidence-based heart failure guidelines in practice.
Definition of Terms
Theoretical Definitions
The following terms were utilized in this project:
1.

Heart Failure: is the heart’s inability to pump oxygen-rich blood (Chen, 2014).
Heart failure is a serious condition that affects the left/right or both sides of
the heart. Right-sided heart failure interferes with the heart’s ability to
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adequately profuse the lungs with oxygen. Left-sided heart failure interferes
with the lungs’ ability to adequately profuse the body with oxygen (National
Heart, Lung, and Blood Institute [NHLBI], 2014).
2.

Evidence-based practice: the incorporation of research supported by evidence,
practice, and patients’ perspectives to improve clinical decisions for patients
(Agency for Healthcare Research and Quality [AHRQ], n.d.). Research
methods conducted by nurses, clinicians, and other healthcare disciplines,
including quasi-experimental designs, descriptive research, qualitative
research, randomized controlled trials, and expert opinion are employed for
clinical practice (Puddy & Wilkins, 2011; Titler, 2008). The integration of all
these components into clinical decision-making enhances opportunities for
patients to receive better quality of life and clinical outcomes (“Introduction to
Evidence-Based Practice,” n.d.).

3.

Hospital readmission: a repeat admission to a hospital before being out of the
hospital for 30 days (Centers for Medicare and Medicaid Services [CMS],
2014).

4.

National guidelines for treating heart failure: evidence-based guidelines that guide
healthcare providers in their decisions about managing heart failure
(Lidenfield et al., 2010; Yancy et al., 2013).

Operational Definitions
For the purposes of this study the following operational definitions were
employed:
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1.

Heart Failure: the primary diagnosis associated with patients’ readmissions. A
diagnosis of heart failure will be identified using the patients’ admission
diagnosis and/or an ICD-9 code as displayed in Table 1.

2. Readmission: For this study, readmissions were defined as a subsequent hospital
admission within 30 days of, discharge as identified by the healthcare
institution’s medical records database.
3.

Pharmacological guidelines for treating heart failure: The ACCF/AHA guidelines
for pharmacological management of heart failure are listed in Table 2.

Table 1
ICD – 9 Codes for Heart Failure
ICD-9 CODE

ICD-9 CODE DESCRIPTION

428.0

CONGESTIVE HEART FAILURE UNSPECIFIED

428.1

LEFT HEART FAILURE

428.20

UNSPECIFIED SYSTOLIC HEART FAILURE

428.21

ACUTE SYSTOLIC HEART FAILURE

428.22

CHRONIC SYSTOLIC HEART FAILURE

428.23

ACUTE ON CHRONIC SYSTOLIC HEART FAILURE

428.30

UNSPECIFIED DIASTOLIC HEART FAILURE

428.31

ACUTE DIASTOLIC HEART FAILURE

428.32

CHRONIC DIASTOLIC HEART FAILURE

428.33

ACUTE ON CHRONIC DIASTOLIC HEART FAILURE

428.40

UNSPECIFIED COMBINED SYSTOLIC AND DIASTOLIC HEART
FAILURE
9

428.41

ACUTE COMBINED SYSTOLIC AND DIASTOLIC HEART
FAILURE

428.42

CHRONIC COMBINED SYSTOLIC AND DIASTOLIC HEART
FAILURE

428.43

ACUTE ON CHRONIC COMBINED SYSTOLIC AND DIASTOLIC
HEART FAILURE

428.9

HEART FAILURE UNSPECIFIED

Adapted from Centers for Medicare and Medicaid Services, n.d.

Table 2
Stages of Heart Failure
Stage

Pharmacological Guideline

STAGE A
- at risk for heart
failure
- has conditions
such as high blood
pressure or
diabetes

1. Treatment with an angiotensin-converting enzyme inhibitors
(ACEI) or angiotensin receptor blockers (ARB), as appropriate, to
control the conditions that might contribute to heart failure.
2. Treatment with statins, as appropriate, in these patients as well.

STAGE B
- at risk for heart
failure due to heart
disease
- no signs and
symptoms of heart
failure present

1. An ACEI or ARB is recommended, as appropriate, to prevent
heart failure
2. Beta-blockers (BB) are recommended, as appropriate, to prevent
heart failure.
3. Statins are recommended, as appropriate, in patients with a
history of heart attack to prevent heart failure.
4. ACEIs and BBs are recommended, as appropriate, with an
ejection fraction (EF) < 35% to prevent heart failure

STAGE C
- heart disease
present
- has signs and
symptoms of heart
failure presently or
in the past

Reduced EF
1. An ACEI, ARB, or BBs recommended if appropriate.
2. Diuretics are recommended, as appropriate, to relieve fluid
retention.
3. Aldosterone antagonists (AA) are recommended, as appropriate,
to reduce effects of the disease and the occurrence of death.
4. Hydralazine and Isosorbide Dinitrates are recommended, as
appropriate, if the patient cannot tolerate an ACEI or an ARB.
5. Digoxin is recommended, as appropriate, to decrease
hospitalization.
Preserved EF
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1. ACEIs, ARBs, and BB can be used, as appropriate, to control
blood pressure.
2. Diuretics are recommended, as appropriate, to relieve symptoms
of volume overload.
3. AAs may also be used, as appropriate, in heart failure patients to
decrease their chance of hospitalization.

STAGE D
- advanced heart
failure or endstage heart failure
- heart failure
symptoms occur at
rest

Advanced pharmacological treatment, such as inotropic agents, is
recommended for patients in this category.

Adapted from Yancy et al., 2013, p. e284.

Assumptions
The following assumptions applied to this study:
1. Evidence-based guidelines are adhered to in healthcare institutions, especially
hospitals.
2. Documentation would be sufficient throughout the patients’ medical records thus
increasing the probability of sufficient information to be collected and
analyzed for this study.
Limitations, Scope, and Delimitations
The primary limitation of this study was the small sample size. The researcher
was only able to examine a total of 31 charts, due to chart availability and the limited
number of staff available to pull more charts. The results of the study did indicate a
possibility of a relationship among the variables if more data were available for analysis.
A further limitation of the study was the lack of generalizability beyond the patients
included in the sample. This was due to small sample size and the limitation of one
setting for data collection. The findings from the study were expected to increase
11

awareness on the importance of utilizing evidence-based research in the management of
heart failure, as well as other diseases. The findings were also expected to illustrate the
importance of sufficient documentation in the patients’ medical records due to the
identification of insufficient documentation while conducting data collection.
Significance of the Study
There is an unfortunate paucity of literature that compares practice patterns at
Mississippi hospitals with national evidence-based guidelines for treating heart failure.
As mentioned, the prevalence of heart failure in Mississippi is significant. Heart failure
has been cited as one of the most prevalent discharge diagnoses in Mississippi, and one of
the primary causes of death in Mississippi patients. There are data that explicate
Mississippi readmissions data; however, there are not data available to compare
guidelines Mississippi hospitals use to reduce admissions with those of national
evidence-based practice guidelines.
Findings from the study aspires to offer additional knowledge about gaps in the
implementation of clinical practice guidelines in the management of Mississippi patients
with heart failure. Further, the study contributes rudimentary data for future research that
might inform best pharmacological practices for reducing readmissions among those
patients. Finally, the findings of this study informs healthcare practices and possible
changes amenable to health policies.
Summary
Chapter I introduced a serious healthcare problem the nation, and particularly
Mississippi, faces heart failure. Chapter I also introduced the impact readmissions have
on the healthcare system. This chapter provided the initial foundation for this study by
12

describing the purpose of this study, the research questions used to guide the study, and
the theoretical framework used to support the study. The theoretical and operational
definitions utilized throughout this study were defined. A description of the assumptions,
limitations, and scope were also provided, as well as a description of the study’s
significance. Chapter II reviews the literature related to the utilization of evidence-based
guidelines and readmissions.
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CHAPTER II – REVIEW OF LITERATURE
Introduction
This literature review consisted of research related to evidence-based guidelines
for the treatment of heart failure, studies related to the utilization of those guidelines, and
studies related to heart failure readmissions. Databases and search engines accessed for
this literature review included Medline, EBSCOhost, ScienceDirect, Dissertation and
Theses, and CINAHL with full text. Research findings were limited to those written in
English. Keywords searched included: evidence-based guidelines, heart failure,
evidence-based therapies, angiotensin-converting enzymes inhibitors, angiotensinreceptor blockers, aldosterone antagonists, beta blockers, readmissions, and Mississippi.
American College of Cardiology Foundation/American Heart Association Heart Failure
Guidelines
The ACCF/AHA developed a comprehensive set of guidelines to assist health
care professionals to manage heart failure patients, which the literature divides into eight
sections. Sections one and two introduce the guidelines and define heart failure,
respectively. Section three examines the four classifications of heart failure, and section
four explores the epidemiology of the disease. Section five discusses the causes of heart
failure, divided into cardiac structural abnormalities and other causes. Section six
provides recommendations for the patient’s initial evaluation as well as the serial
evaluations that will follow. Section seven presents the recommended treatment for the
disease based on each progressive stage of heart failure. The final section, section eight,
describes how to care for a heart failure patient during hospitalization (Yancy et al., 2013,
pp. e241-e242).
14

For the purpose of this study, the researcher explored the pharmacological
treatment recommendations for heart failure. The well-being and ability to perform day
to day activities of those affected with heart failure are predictors of hospital
readmissions (Moser et al., 2009, p. 766). Both the symptoms and management of those
symptoms influence the heart failure patient’s well-being and ability to function. The
care provided embodies the utilization of appropriate treatment for symptoms related to
the disease (Ekman et al., 2005, p. 292).
Four primary pharmacological classes are recognized in the ACCF/AHA
guidelines for treating heart failure: angiotensin-converting enzymes (ACEIs) inhibitors,
angiotensin-receptor blockers (ARBs), aldosterone antagonists (Aas), and beta blockers
(BBs). Diuretics, digoxin, and other medications are recommended in patients with
advanced disease. There are recommendations that these medications be increased in
small doses to achieve optimal guideline-directed medical therapy (Yancy et al., 2013, p.
e276).
Angiotensin-Converting Enzyme Inhibitors
ACEIs block the body’s production of angiotensin II, which constricts blood
vessels. In patients with hypertension, ace inhibitors keep those vessels open because
hypertension is a precursor for heart failure. These medications are especially important
because they decrease the work requirement in the already weakened heart muscle
(Sweitzer, 2003, p. e16). The utilization of these medications has been associated with
reduced mortality, hospitalizations, and repeat hospitalizations. The ACCF recommend
ACEIs in all patients affected by heart disease in an attempt to prevent heart failure. The
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organizations also recommend these medications to prevent symptoms heart failure
patients might exhibit (Yancy et al., 2013, p. e261).
Fu et al. (2012) analyzed seven prospective studies to evaluate their prognostic
effect on chronic heart failure patients with a preserved EF versus other medications.
Researchers found both death due to all-cause and repeat hospitalizations were reduced
with the utilization of these medications. They discovered that the majority of the cases
were due to hypertension (69%). This was followed by 33.7% of the cases catalyzed by
ischemic heart disease and 25.8% of the cases owed to diabetes mellitus.
Sanam et al. (2014) also explored the association between ACEIs and
readmissions by examining the prescriptions of patients with heart failure before
discharge. Similar results were found in that there was a reduction readmissions and
mortality. Shah et al. (2013) contributed to these findings via their study of the effects
ACEIs, along with beta blockers, had on patient outcomes. They performed a repeat
analysis of the Biomarkers in Acute Heart Failure (BACH) trial, an international
prospective study that investigated the presentation of heart failure patients to the
emergency room exhibiting shortness of breath (Maisel et al., 2010). It was found that
patients had an increased chance of survival if discharged on both medications, with the
ace inhibitor serving as the survival agent.
Angiotensin-Receptor Blockers
ARBs are similar to ace inhibitors in that they also regulate the angiotensin II
hormone. These medications inhibit the effect of the hormone, thus lessening the adverse
effects associated with ace inhibitors (Barreras & Gurk-Turner, 2003, p. 123; Terra,
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2003). ARBs are recommended in patients affected by heart disease in an attempt to
prevent heart failure and its associated symptoms (Yancy et al., 2013, p. e261).
There are varying reviews of the utilization of the above-mentioned medications.
According to previous studies, ARBs are beneficial to heart failure patients when used
concurrently with ace inhibitors. There have been limited associations between the sole
use of the medications in the reduction of death and repeated admissions to the hospital;
however, there are studies that suggest they might benefit patients who are intolerant to
ace inhibitors.
Dickstein (2001) reviewed two trial studies, the Elderly Losartan Heart Failure
Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT), to examine
the effect ARBs had on prevalence of the disease and death. Losartan, an ARB, was
compared to captopril, an ACEI, in the ELITE II trial. The Val-HeFT trial investigated
valsartan, an ARB, against a placebo. In both trials, the target dose of medication was
achieved by more than 75% of the patients. Patients tolerated ARBs in both trials;
however, a difference was not seen in death when comparing losartan and captopril in the
ELITE II trial. The author did report, however, that patients taking valsartan as opposed
to the placebo in the Val-HeFT trial did experience a reduction in hospitalization and
death or disease (p. 241).
McMurray (2001) added to this by also reviewing the Val-HeFT and ELITE II
trials along with the Candesartan in Heart Failure: Assessment of Reduction in Mortality
and Morbidity (CHARM), and the Irbesartan in Patients with Heart Failure and Preserved
Ejection Fraction (I-PRESERVE) trial. The same findings were reported as Dickstein
(2001) in that the patients in the Val-HeFT and ELITE II tolerated ARB treatment.
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Additionally, patients on an ARB in the Val-HeFT trial had a reduction in
hospitalizations as compared to those taking a placebo. The CHARM and I-PRESERVE
trials are still in their developmental stages but will compare the utilization of an ARB to
a placebo. Researchers did report that participants in the Study of Patients Intolerant of
Converting Enzyme Inhibitors (SPICE) tolerated candesartan better than an ACEI (pp.
98-100).
Granger et al. (2000) conducted a double-blind randomization study to determine
whether patients’ intolerant of ACEIs could tolerate ARBs. There were 90 different
study sites in seven different countries to obtain a broad perspective, as well as to create a
registry of patients who could not tolerate ACEIs. Participants in the study initially
received either 4 mg of candesartan or 4 mg of a placebo. The medication dosages were
then titrated to 8 mg at 2 weeks and doubled in mg after 4 weeks. If patients continually
tolerated the medications, then dosages were increased to 16 mg. The titration of
medication from beginning to end lasted a total of 12 weeks. They reported that 82.7%
of the participants tolerated the titration of the candesartan and completed the 12-week
program. In addition, they reported that patients taking the medication as opposed to the
placebo were hospitalized less frequently (18.7% vs 12.8%) (pp. 611-613).
Savarese et al. (2013) conducted a meta-analysis of 26 trials comparing ACEIs
and ARBs in patients with high cardiovascular risks but without heart failure. They
found that the combination of medications benefited patients with an increased chance of
developing the disease. These researchers also reported that the literature indicated
ARBs were beneficial in the reduction of mortality and morbidity in patients who
experienced a contraindication to ACEIs (pp. 133-140).
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Aldosterone Antagonists
Aldosterone antagonists (AA) are diuretics that block the effects of aldosterone in
the body, specifically via regulation of fluid volume. This is a major factor in heart
failure patients because they are susceptible to volume overload. Spironolactone and
Eplerenone are commonly used aldosterone antagonists (Maron & Leopold, 2010, pp. 23).
Several studies cite the combination of Aas, BBs, and ACEIs as being beneficial
to heart failure patients. Aas are associated with decreases in mortality and rehospitalizations. Hyperkalemia is an associated drawback to using these medications
(Nappi & Sieg, 2011; Rocha & Williams, 2002). The AHA and ACCF recommend Aas
in heart failure patients with an EF < 35% to reduce morbidity or mortality. They are
also recommended in patients following acute myocardial infarctions that have a reduced
EF of 40% or less (Yancy et al., 2013, p. e268).
Marcy and Ripley (2006) reviewed the functions, benefits, and adverse events that
might occur while using aldosterone antagonists in heart failure. Spironolactone and
eplerenone were identified as the available aldosterone antagonists used in healthcare.
The authors reported that Aas are a pivotal part of treatment in conjunction with other
heart failure treatments. They reported, as previously cited, that the renal function of
heart failure patients and risk of hyperkalemia should be routinely monitored (pp. 49-56).
Miller and Alvarez (2013) reviewed literature in support of Aas and guidelines to
support their use. The authors identified three major trials: the Randomized Aldactone
Evaluation Study (RALES), the Eplerenone Postacute Myocardial Infarction Heart
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Failure Efficacy and Survival Study (EPHESUS), and the Eplerenone in Patients with
Systolic Heart Failure and Mild Symptoms Study (EMPHASIS) (p. E49).
Pitt et al. (1999) conducted RALES to determine whether 25 mg of
spironolactone affected patients at risk for death with end-stage heart failure. The study
included 1663 patients, 822 of which received the initial dose of spironolactone 25 mg
daily, and 841 patients receiving the same dosage of a placebo daily. The medication
dose was doubled at 8 weeks if the patients tolerated the medication without exhibiting
signs and symptoms of hyperkalemia. If the patient did not tolerate the medication, the
medication dosage was titrated down to a smaller dose. The study ended when death
occurred. The authors reported that spironolactone was associated with the heart failure
patients’ reduced risk for death by 30% but also reduced the risk of hospitalizations
caused by cardiac issues by 35% less than the placebo group. The author also reported
that their study further reinforced the premise that ACEIs were insufficient to suppress
the aldosterone hormone, but that Aas had a pivotal part of treating heart failure, as well
(pp. 709-716).
Pitt et al. (2003) conducted the EPHESUS to evaluate eplerenone and its effect on
morbidity and mortality of heart failure patients who had experienced a myocardial
infarction. Six thousand six hundred and forty-two patients participated in the study,
with 3313 receiving eplerenone and 3319 receiving the placebo. An initial dose of 25 mg
was given to the eplerenone and placebo group. The participants also received optimal
medications in conjunction with the study meds. The study ended when death occurred
among the participants. The authors reported that more deaths occurred in participants
who received the placebo than those who received eplerenone. Cardiovascular-related
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issues caused death in both groups. The authors reported that participants in the
eplerenone group (12.3%) experienced fewer deaths resulting from cardiac causes than
participants in the placebo group (14.6%) (pp. 1309-1321).
Zannad et al. (2011) also conducted a study of the drug eplerenone to determine
its effect on patients (n = 2,737) with left-sided heart failure exhibiting symptoms. There
were two study groups: eplerenone group (n = 1364) and a placebo (n = 1373). The
patients also received additional pharmacologic systolic heart failure therapy.
Participants initially received a daily dose of 25 mg of eplerenone or the placebo. If the
patient tolerated the medication, the daily dosage was doubled. The end point primary
outcomes of the study were either death or hospitalization. The authors reported that
patients taking eplerenone had a smaller risk of deaths and hospitalizations than those
receiving a placebo. There were fewer deaths in the eplerenone group (18.3%) than in
the placebo group (25.9%) (pp. 11-20).
Beta Blockers
BBs block beta-adrenergic receptors in the body. They decrease the workload of
the heart by slowing the pulse and lowering blood pressure. These medications are a
common treatment option for patients with hypertension (AHA, 2015c). They should
also be used in conjunction with other medications when treating heart failure (Chavey,
2000; Gheorghiade, Colucci, & Swedberg, 2003). The AHA and ACCF recommend BBs
in all patients with an EF < 35%. They are also recommended in patients with a heart
attack and an EF < 35% to prevent heart failure (Yancy et al., 2013, p. 261). In previous
studies, authors have cited a relationship between BBs and a reduction of mortality,
improved quality of life, and a reduction in hospital readmissions.
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Chang, Yang, Freeman, Hlatky, and Go (2013) performed a study to determine
their effectiveness in patients (n = 668) with heart failure and chronic kidney disease.
Pharmacy databases were used to collect data on medication utilization among the
participants in the study. Participants were included in the study if pharmacy data
revealed BB utilization among patients twelve months or longer. The authors reported
that patients beyond 80 years of age seldom initiated the medication, and participants
who initiated them into their pharmacotherapy regimen reduced their risk of death and
hospitalization (pp. 176-181).
Packer et al. (2001) analyzed the survival rate of patients with end-stage heart
failure taking carvedilol. The study’s patients (n = 2,289) were divided into a carvedilol
(n = 1156) and placebo group (n = 1133). Both groups received a dose of 3.125 mg two
times a day for 14 days. Medications dosages were doubled every 2 weeks if the patients
tolerated the titrations until the goal of 25 mg twice daily was achieved. Death and risk
of death or hospitalization were the end-points of the study. The authors reported that
carvedilol was tolerated well by the patients. Patients in the placebo group had to
discontinue their treatment early as opposed to patients in the carvedilol because of
adverse effects. The authors also reported that adding carvedilol to the patients’
medication regimen produced substantial effects towards their survival.
The rate of death in patients receiving carvedilol was reduced by 35%. The risk of death
and hospitalizations were reduced by 24% (pp. 1651-1657).
Taneva and Caparoska (2016) conducted a study on chronic heart failure patients
to determine whether BBs had an impact on death and death and/or hospitalizations
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related to cardiovascular issues. One hundred and thirteen patients were evaluated for 2
years. The patients were divided into participants receiving a beta blocker and a control
group. Patients in the beta blocker group received a beta blocker along with conventional
heart failure therapy. Conventional therapy was the only treatment received in the control
group. Conventional therapy included diuretics, cardiac glycoside, and ACEIs. The beta
blocker group was further divided into three subgroups with each group receiving a
different beta blocker: metoprolol, bisoprolol, and carvedilol. The authors reported that
the risk of death was reduced by 34% in the beta blocker group, and the combination of
death and/or hospitalization was also reduced by 40% (pp. 94-97).
Gomez et al. (2011) performed a prospective study (n = 1,085) to determine the
relationship between death and incidence of disease of heart failure patients with a
preserved systolic function and the treatment of BBs. The study took place over a course
of 5 years. The medications under review were bisoprolol and carvedilol. Pharmacy
databases were utilized to monitor compliance as well as other routine heart failure
medications. The authors reported that morbidity, mortality, and hospital admission were
all reduced by BBs. Patients with newly diagnosed preserved systolic function and being
treated with BBs experienced a reduced risk of death by 28% for those related to all
causes and by 41% for those related to the heart. The incidence of the disease was also
reduced as evidenced by the reduced risk of hospitalization (24%) and reduced risk of
repeat admission to the hospital (23%) (pp. 51-55).
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Utilization of Evidence-Based Heart Failure Guidelines and
Its Impact on Morbidity and Mortality
Gislason et al.’s (2007) retrospective study evaluated evidence-based
pharmacotherapy in heart failure patients. They examined the relationship between
initiation, underdosing, or early termination of pharmacotherapy and the underuse of
pharmacotherapy. In this study, the medical treatment of adults (n = 107,092)
hospitalized for the first time with heart failure and discharged between 1995 and 2004
were reviewed. Medical treatments were examined for BBs, ACEIs and ARBs,
spironolactone, and statins. The authors used logistic regression to assess trends between
initiation of treatment and patient mortality. Multivariable analysis was used to assess
the trends between mortality and break in therapy for 90 or more days. The authors
reported an increase in initiation of medical treatment between 1995 and 2004: ACEIs
and ARBs (35.9% to 49.6%), BBs (12.1% to 42.7%), spironolactone (9.8% to 24.9%),
and statins (2.0% to 26.9%). In addition, clinicians were routinely prescribing
medications below the recommended doses and failing to increase the dosages during
long-term treatment. The authors also reported that the persistent use of treatment
contributed to a decrease in mortality between 1995 and 2003 (38.7% to 34.5%) (p. 739).
Asghar and Rahko (2010) compared adherence to 2005 ACCF/AHA guidelines
when utilizing implantable cardioverter-defibrillators (ICD), cardiac resynchronization
therapy (CRT), and medication therapy between heart failure clinicians and general
cardiologists. The authors retrospectively reviewed charts of adult patients seen in a
heart failure clinic (n = 324) or general cardiologist clinic (n = 239) between 2005 and
2006. The authors looked for patients who had chronic left ventricular dysfunction
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confirmed by imaging and stage C heart failure. Three hundred and twenty-four charts
met criteria in the heart failure clinic, and 239 charts met criteria in the general
cardiologist clinic. They reported that both the heart failure clinicians and general
cardiologists followed the guidelines for CRT (86% vs. 81%) and placement of ICDs
(77% vs. 74%). There was a difference however in the heart failure clinicians and
general cardiologists’ implementation of guidelines when treating heart failure (97% vs.
82%). Patients receiving guideline-recommended medicines had a > 35% improvement
in their EF (pp. 65-69).
Fonarow et al. (2011) investigated the potential impact of failing to comply with
guidelines to implementing optimal evidence-based therapies on heart failure mortality.
The authors identified six evidence-based guideline-recommended therapies that reduced
death in those affected by the disease. The recommended therapies included
conventional heart failure therapy along with hydralazine/isosorbide dinitrate, CRT, and
ICD. A representative sample of patients (n = 2,644,800) was drawn from inpatient and
outpatient heart failure registries as well as studies that examined heart failure quality of
care. They compared the patients who were eligible for and treated with the
recommended therapies against those patients who were also eligible for treatment but
were not treated.
Researchers reported that a significant number of eligible patients did not receive
the recommended therapies. A significant number of eligible patients did not receive
hydralazine/isosorbide dinitrate (92.7%) while the lowest number of eligible patients did
not receive recommended BBs (14.4%). Additionally, a significant number of eligible
patients did not receive an ACEI or an ARB (20.4%), an AA (63.9%), CRT (61.2%), or
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ICD (49.4%). The results indicated that full implementation of all six therapies had the
potential to prevent 67,996 deaths a year, and the implementation of evidence-based BBs
alone had the potential to prevent 21,357 deaths (pp. 1025-1027).
Majumdar et al. (2004) examined the benefits of using high-dose ACEIs, BBs,
and digoxin in 3,164 patients with advanced heart failure in 19 different countries
between 1992 and 1994. Medication utilization was the dividing factor between the
groups. Ninety-one percent of the patients analyzed in the study were still on their initial
treatment regimen. The results revealed that patients receiving all evidence-based
therapies had a reduced rate of death and hospitalization (12%) at 1 year as compared to
those who received only low-dose ACEIs. The results also indicated that patients taking
only low-dose ACEIs plus digoxin were an increased risk for all-cause mortality (pp.
694-699).
Yancy et al.’s (2010) prospective study assessed the utilization of ACCF/AHA
guideline-recommended therapies in U.S. outpatient cardiology clinics between 2005 and
2007. The authors assessed for the following measurements: (a) pneumococcal vaccines,
(b) utilization of isosorbide dinitrate/ hydralazine specifically in Black patients, (c) statin
and antiplatelet therapy, (d) cholesterol levels, (e) smoking cessation counseling, and (f)
blood pressure controls.
The results of the study showed that the mean adherence for HYD/ISDN was
7.3%, and more than 71% of the outpatient practices failed the HYD/ISDN measurement.
Outpatient practices were also significantly deficient in the other measurements. The
results ranged from as low as 1.2% for pneumococcal vaccination to 80.8% for blood
pressure controls. The results of the study indicated that outpatient practices were
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deficient in their conformity to guideline-recommended heart failure therapy and that
better processes were needed to promote adherence to guideline-recommended therapy
(pp. 255-260).
The first part of this literature review provided an overview of the four
pharmacological classes used in the ACCF/AHA’s guidelines in disease management.
The four classes consisted of ACEIs, BBs, ARBs, and Aas. This section explored the
function of each pharmacological class and studies that supported their use in disease
management. Studies were also provided on the utilization of the pharmacological
classes in treatment and their impact on morbidity and mortality. The second part of the
review provided below discussed the guidelines and their impact on hospital admissions
and readmissions.
Utilization of Evidence-Based Heart Failure Guidelines and Its Impact on
Hospital Admissions and Readmissions
Numerous programs and strategies have been implemented to reduce
readmissions; however, the numbers of readmissions in healthcare institutions remain
steady. The hospital is a central location for heart failure patients to receive care.
Hospitals are sometimes the first stop for patients to receive heart failure diagnostics and
to learn about living with heart failure. These offerings are often insufficient. After
discharge, patients still need to be monitored and medications should be adjusted
accordingly. If evidence-based therapies are not taken into account, patients are put at an
increased risk for readmission.
Gheorghiade, Vaduganathan, Fonarow, and Bonow (2013) offered insight into
strategies that may help reduce readmissions. They discussed the influence symptoms
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had on readmissions, monitoring heart failure patients and their disease, and utilization of
evidence-based therapies in their treatment. Further, they classified a low ejection
fraction and the symptom of congestion as being high risk for readmission. One can
conclude that hospitals could reduce readmissions by performing comprehensive patient
assessments to evaluate not only the physical characteristics and comorbidities of the
patients but the social circumstances that might contribute to readmissions, as well. The
authors submit that though the patient’s hospital admission was important, the postdischarge phase was a vulnerable period for the patient. As such, patients and their
families play significant roles in bridging that transitional phase between the hospital and
home. Through collaborative efforts between the patient and the healthcare team,
readmissions are expected to decline (pp. 395-401).
Kociol et al. (2012) explored the national trends of hospitals and heart failure
readmissions. One hundred randomly selected hospitals were contacted via telephone
that participated in the Get with the Guidelines-Heart Failure (GWTG-HF) quality
improvement program, the extent to which the program had any impact on the reduction
of heart failure readmissions. The program aims to improve the care patients receive in
hospitals by supporting consistent use of today’s evidence-based research (AHA, 2015b).
The survey addressed three vital processes that affect readmissions: (a) the care patients
receive while in the hospital, (b) the care patients receive at discharge, and (c) the overall
quality of care received. The authors used linear regression to analyze the relationship
between those processes and the readmission rates of the surveyed hospitals. Results of
the study indicated that the hospitals did participate in strategies to improve inpatient care
and the overall quality of care received. The results also indicated care received at
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discharge were associated with a reduction of readmission rates (Kociol et al., 2012, pp.
681-685).
Heidenreich et al. (2012) also performed a study to determine whether the
program improved processes of care in hospitals that used the program as opposed to
hospitals that did not. The hospitals’ enrollment period was 2006 to 2007. The study
included 4,460 hospitals. Of those 4,460 hospitals included in the study, 215 (5%) of the
hospitals participated in the GWTG-HF and the other 4,245 (95%) did not participate in
the study.
The hospitals had to address four processes valuable to the treatment of heart
failure as determined by CMS; they were (a) assessment of the patient’s left ventricular
function, (b) use of an ACEI or ARB to treat left ventricular systolic dysfunction or a
reduced EF, (c) discharge teaching, and (d) counseling for smoking cessation. The
researchers used Pearson X2, Wilcoxon rank-sum tests, and multivariable logistic
regression analyses to analyze the data. The results indicated hospitals that participated
in the program reflected better scores in regards to the documentation of left ventricular
ejection fraction, utilization of recommended medications, and teaching at discharge. A
difference was not seen among counseling for smoking cessation between the two sets of
hospitals. The results also indicated that hospitals participating in the program had lower
all-cause readmission rates than hospitals that did not participate in the program (pp. 3739).
Yoo et al. (2014) performed a retrospective, observational study to examine
whether Korean hospitals adhered to guidelines when treating systolic heart failure. The
study population included 1,297 patients with admittance to 23 university hospitals in
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2009. The authors determined compliance by assessing for the use of three
pharmacological classes: (a) ACEI/ARB, (b) BB, and (c) AA. They also examined the
clinical outcomes of the patient, which included (a) 90-day mortality, (b) 1-year
mortality, (c) re-hospitalizations, and (d) mortality and re-hospitalizations. The study
population was divided into two groups: patients with good guideline adherence and
patients with poor guideline adherence. The authors defined good guideline adherence as
the utilization of greater than or equal to 50% of the pharmacological classes, while bad
guideline adherence involved utilization of less than 50% of guideline adherence to the
pharmacological classes.
The results of the study were as follows: (a) ACEI or ARB were adhered to the
most in treatment at 89.7%; (b) BB’s were second to be adhered to at 69.2%; and (c) the
AA’s were third to be adhered to at 65.9%. Results indicated that overall there was good
adherence to the three pharmacological classes. Patients with good guideline adherence
enjoyed a survival rate of 96.7% and a re-hospitalization rate of 62.3%, as opposed to
patients with bad guideline adherence who experienced a survival rate of 89.8% and a rehospitalization rate of 56.4% (Yoo et al., 2014, pp. 1-7).
Krantz et al.’s (2011) prospective study examined evidence-based heart failure
medications in hospitalized patients from admission to discharge in an attempt to reduce
death and hospitalizations. The study population consisted of 9,474 patients admitted to
hospitals enrolled in the GWTG program. Researchers assessed for the utilization of
three pharmacological classes: ACEIs/ARBs, BBs, and Aas. Prior to hospital admission,
a significant number of patients were eligible for recommended therapies. Ninety-three
percent of the patients met eligibility for a BB. This was followed by more than 70% of
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the patients being eligible for the two remaining pharmacological classes. During
hospital admission, 72.6% of eligible patients were given BBs, and an ACEI /ARB was
also administered to 65.3% of the eligible patients. Aldosterone antagonists were the
least pharmacological class given to eligible patients at 15.6%. More than 90% of the
eligible patients received a BB or an ACEI/ARB at discharge. The least number of
eligible patients (32.2%) received an AA. The initiation of the three pharmacological
classes at admission were predictors of continued use at discharge of the patients (pp.
1818-1823).
Calvin et al. (2012) reported the results of the Heart Failure Adherence Retention
Trial (HART), which studied the adherence of both physician and patient to evidencebased guidelines for heart failure. Two classifications of medications were primarily
examined: (a) ACEI/ARBs, and (b) BB. They defined physicians as being non-adherent
if any of those medications were prescribed when contraindicated, or physicians failed to
prescribe any of those medications to patients without contraindications. The authors
determined patient adherence by using MEMS electronic pills caps to measure the
number of times patients opened their medication bottles and by comparing those
numbers to medication regimens prescribed by the physician. Patients were considered
adherent if they took their medication more than 80% of the time.
The study consisted of 692 patients recruited from hospitals throughout the
greater Chicago area. Patients were recruited with a systolic dysfunction or EF of less
than 40%. The authors reported that 63% of physicians were adherent to guidelines when
treating heart failure. There were more patients with contraindications on therapies than
those without contraindications that should have been recommended therapies. BBs were
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prescribed to 35 out of 51 (68.6%) patients with contraindications and ACEIs/ARBs were
prescribed to 40 out of 54 (74.1%) patients with contraindications. The authors also
reported that 213 out of 581 (37%) patients did not consistently take their prescribed
medications; however, the overall non-adherence rate for both physicians and patients
was 59%. An interesting finding of the study was that minority status of the patients was
associated with their non-adherence. Physician non-adherence was associated with four
factors: minority status of the patient (which was not defined in the study), comorbidities
of the patients, age of the patients, and advanced stages of heart failure (Calvin et al.,
2012, pp. 73-78).
Summary
This literature review discussed research related to evidence-based guidelines for
the treatment of heart failure, studies related to the utilization of evidence-based
guidelines in the treatment of heart failure, and studies related to heart failure
readmissions. The literature review provided research that supported the utilization of
evidence-based pharmacologic treatment in practice and its impact on patients’ outcomes
(Asghar & Rahko, 2010; Calvin et al., 2012; Fonarow et al., 2011; Gislason et al., 2007;
Majumdar et al., 2004; Yancy et al., 2010). Asghar and Rahko (2010) and Yancy et al.
(2010) specifically looked at the utilization of ACCF/AHA pharmacological guidelines in
the pharmacological treatment of heart failure patients. Though research demonstrated
positive outcomes for patients receiving evidence-based pharmacotherapy, researchers
reported varying degrees of conformity to use of evidence-based guidelines in practice.
Several studies in the literature occurred in hospitals and clinics in the United States and
other countries. The limitation of this review was the lack of research on utilization of
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the guidelines in the state of Mississippi. This finding supports the study’s research
question of determining to what extent are Mississippi hospitals adhering to evidencebased pharmacological management guidelines for the management of heart failure.
Pharmacologic treatment not specific to the ACCF/AHA guidelines was also
explored. The authors reported that patients did receive an initial treatment of evidencebased pharmacotherapy; however, some clinicians did not increase doses as
recommended. In addition, some patients eligible for evidence-based pharmacotherapy
did not receive them.
Gislason et al. (2007) evaluated evidence-based pharmacotherapy in heart failure
patients and discovered that patients received insufficient dosages of the recommended
therapies. The authors also reported that the initial dosages remained the same onward.
Another key finding the authors reported in the study were that age, living arrangements,
and socioeconomic factors all played a part in medication persistence. Patients of
advanced age and who lived alone reflected poorer medication persistence. Additionally,
the socioeconomic factor of increased medication costs also contributed to medication
persistence (p. 739)
The study completed by Majumbar et al. (2004) produced similar results in
regards to medication dosages. The authors performed a secondary analysis of the
Assessment of Treatment with Lisinopril and Survival Trial (ATLAS), a study that
examined the effect low and high doses of ACEIs had on death and incidents of the
disease (Packer et al., 1999). The results of the study showed that patients receiving
higher doses of ACEIs along with the evidence-based dosages of other heart failure
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therapies had greater benefits, such as a reduction in mortality or hospitalization (pp. 697701).
Fonarow et al.’s (2011) study did not offer probable explanations as to why there
was not conformity to evidence-based heart failure therapies; however, the study
quantified current treatment gaps and the number of preventable deaths with the
implementation of therapies. The authors reported that a significant number of eligible
patients (n = 2,644,800) were not being treated with the recommended ACEIs/ARBs (n =
501,767), BB (n = 361,809), or Aas (n = 385,326). The numbers were also significant for
the number of deaths related to not receiving the recommended therapies. The authors
reported that the deaths of these patients (n = 67,996) be prevented if patients received
the optimal implementation of guideline-recommended treatment (pp. 1025-1027).
Several of the studies supported the premise that evidence-based therapies in the
management of heart failure patients were able to increase survival rates and reduce
hospital readmissions (Gheorghiade et al., 2013; Heidenreich et al., 2012; Kociol et al.,
2012; Krantz et al., 2011; Yoo et al., 2014). Heidenreich et al. (2012), Kociol et al.
(2012), and Krantz et al. (2011) studied the impact using the GWTG program had on
readmissions and reported that use of the guidelines contributed to the reduction of heart
failure readmissions. Calvin et al.’s (2012) study focused on physician and patient
adherence to evidence-based guidelines in the Chicago area. The results indicated the
both patients and physicians had an issue with adherence to guideline-recommended
therapies.
Overall, the literature lacks research about the evidence-based pharmacotherapy
used to treat heart failure patients in Mississippi. Identifying whether Mississippi heart
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failure patients are receiving evidence-based therapies might be the start to filling the gap
regarding the utilization of evidence-based pharmacotherapy in Mississippi. This
understanding might help guide development of strategies for encouraging adherence to
practice guidelines with the possibility of curbing costs associated with readmission rates
of Mississippi heart failure patients. Studies in different geographic regions are also
important because they can help identify the needs of patients and physicians specific to
those regions. Information from that study can also assist in the creation of policies and
programs that tailor to the needs of people in those communities (Casper et al., 2010, p.
299).
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CHAPTER III - METHODOLOGY
Introduction
Chapter III outlines the steps taken for implementation of the current study.
Provided is information on the setting, sample, steps taken to protect participants, data
collection techniques, and how data analysis was engaged. The researcher conducted an
exploratory study to evaluate the relationship of adherence to evidence-based guidelines
for pharmacologic management by selected Mississippi hospitals and their hospital
readmission rates. A retrospective design was used in this study, as it offered insight into
the relationship between readmissions of heart failure patients and adherence to the
national guidelines for the pharmacologic treatment of heart failure.
Setting
The setting for this exploratory study was a 400-bed health care institution located
in the southeastern region of the United States. The selected healthcare institution is one
of the largest medical systems in that state and region, offering two hospitals and a
variety of healthcare clinics. Several other hospitals were approached for inclusion, but a
plethora of barriers prevented their participation. Although it cannot be substantiated, it
seemed as though a few of the approached hospitals were reluctant to have records
evaluated that would have determined their quality of congestive heart failure treatment
and care.
Sample
The researcher collected sample data for this study from a database of medical
records of patients with heart failure seen between January 2011 and June 2014. The
sample data were used to measure adherence to pharmacotherapy recommendations.
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This time period was chosen because readmission data received from data.medicare.gov
(2015b) specified these date ranges as the dates of analysis for readmissions in
Mississippi. Date ranges are also a significant factor in retrospective studies. A 4-year
span was chosen to maximize the study’s efficacy by increasing the number of
hospitalizations that qualified as readmissions. The researcher limited the study to the
first 30 days of the patient’s index hospitalization and readmissions included in that
period.
Patient inclusion criteria for this study included the following components: 18
years of age and older with a diagnosis of heart failure as identified by the International
Classification of Disease (ICD – 9) Codes for heart failure (Table 1). ICD-9 codes were
used because hospitals did not begin using ICD-10 codes until October 2015.
Hospitalizations that met inclusion criteria were identified by a list of 30-day
readmissions provided by administrators at the healthcare institution.
The researcher determined through a power analysis 80 medical records would be
an adequate sample size for this study. A convenience sample was utilized to select
subjects. The researcher was able to collect 31 of the required charts needed for review.
This limited number of charts was due to chart availability and the limited number of
staff available to pull an adequate number of charts.
Protection of Human Subjects
The University of Southern Mississippi’s Institutional Review Board (Appendix
B) and the IRB of the selected healthcare institution in Mississippi (Appendix C)
approved this exploratory study. There were no known risks to the participants or the
information the researcher obtained in this study. The researcher did not recruit any
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patients but instead used confidential retrospective data only from medical chart reviews.
Data were collected in a private room provided to the researcher by the healthcare
institution. This measure reduced the risk of accidentally disclosing confidential
information as the medical charts were reviewed. The researcher ensured that data
obtained from the records were non-identifiable and kept confidential. The researcher
achieved confidentiality by not collecting personal information, such as names,
addresses, and/or social security numbers. The researcher also replaced medical record
numbers with researcher created identification numbers assigned only for this study.
Data were entered the same day it was collected as well as stored on a laptop with
password-protected software. The researcher took the protection of data a step further by
securing the laptop and data abstraction tool, used to collect data, in a locked file cabinet.
Data Collection
Following USM IRB approval and approval from the selected healthcare
institution, data for this study were obtained by the researcher from medical records at the
approved healthcare site. The researcher requested permission to access the medical
records of patients with the primary admission diagnosis of heart failure. The researcher
created a simple data abstraction tool (Appendix A) to collect data on the variables of
interest: demographic variables and clinical variables. Data abstraction tools add to the
validity of retrospective studies by guiding data collection and ensuring that data is
collected in a uniform manner (Schwartz & Panacek, 1996, p. 123). A well-designed
data abstraction tool limits the chance of missing data, increases the likelihood accurate
data is collected and promotes the analysis of accurate data (Banks, 1998, p. 164). The
researcher utilized the data collection tool to determine whether the ACCF/AHA
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guidelines were adhered to by seeking documentation that included the four
pharmacological classes in the patients’ treatment at admission and discharge and then
again at the patients’ readmission and discharge.
The demographic variables of interest included age, gender, and ethnicity. Age,
gender, and ethnicity of the patients were obtained from the patients’ admission
demographic paperwork. Age was confirmed by the patients’ date of birth. Gender was
defined as the patients’ biological construct: male or female. This information was
designated on the patients’ chart.
The clinical variables of interest included admission date, discharge date, and
readmission date, stage of heart failure, ICD-9 code diagnosis of heart failure,
comorbidities (diabetes, hypertension, myocardial infarction, atrial fibrillation, ischemic
heart disease, hyperlipidemia, anemia, chronic kidney disease, and chronic obstructive
pulmonary disease), height, weight, lab findings (blood urea nitrogen (BUN), creatinine,
potassium, brain natriuretic peptide (BNP), hemoglobin a1c, and hemoglobin), admission
and discharge vital signs, heart failure medications at index admission/discharge and
readmission/discharge , and smoking status (current smoker, past smoker, and never
smoked). The researcher also collected the payer sources for this hospitalization of the
sample participants, which may include Medicare, Medicaid, private insurances, and noninsured. The data were entered into Excel and imported into a statistical software
package for data analysis.
ICD-9 codes were either identified on the patients’ demographic admission
paperwork or the case manager’s discharge planning notes. When the ICD-9 code for
heart failure was not available to confirm the patients’ diagnosis admission of heart
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failure, the researcher then reviewed the physician’s dictated history and physical for the
inclusion of the diagnosis of heart failure in the reason for admission diagnoses. The
researcher used the criteria displayed in Table 2 to determine the stage of heart failure
among the patients. The confirmation of stage C heart failure among the patients was
confirmed by the emergency room’s documentation of the patients’ heart failure
symptoms exhibited upon admission, as well as the physician’s documentation in the
history and physical of the patients’ heart failure symptoms exhibited upon admission.
Information regarding patients’ height, weight, lab values, comorbid conditions,
vital signs, and smoking status were obtained from chart reviews. Height and weight
were obtained from the patients’ admission paperwork. Lab values were obtained at
admission from the patients’ laboratory paperwork. Index admission and discharge vital
signs were obtained at the patients’ initial admission from the graphic’s section in the
patients’ chart. The researcher focused primarily on patients’ blood pressure and pulse.
The selected comorbid conditions on the data abstraction were identified in the
ACCF/AHA guidelines as being comorbid conditions that commonly affect heart failure
patients (Yancy et al., 2013, p. e294). The patients’ comorbid conditions were obtained
from the physician’s dictated history and physical, consultation notes, and discharge
notes. Smoking status was obtained from the physician’s dictation of the patients’
smoking status in either the patients’ history and physical or consultation notes. The
patients’ payor sources were also identified by the patients’ demographic data.
Finally, the patients’ medication information was obtained from the medication
lists at admission and discharge and again from the medication lists at readmission. Each
class of medication was recognized by utilizing a list created by researcher of commonly
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used medications according to each medication class. The referral list is provided in
Table 3.
Table 3
Common Heart Failure Medication Classes
ACEI

BB

ARBS

- end in pril

- end in lol

- end in tan

Benazepril
(Lotensin)
Captopril
(Capoten)
Enalapril
(Vasotec/Epaned)
Fosinopril (Monopril)

Acebutolol
(Sectral)
Atenolol
(Tenormin)
Betaxolol
(Kerlone)
Bisoprolol
Fumarate (Zebeta)
Carvedilol
(Coreg)
Esmolo
(Brevibloc)
Lebetalol
(Trandate)
Metoprolol
(Lopressor)
Nadolol
(Corgard)
Nebivolol
(Bystolic)
Penbutolol
(Levalol)
Propranolol
(Inderal LA, Inderal
XL)

Candesartan
(Atacand)
Eprosartan
(Teveten)
Irbesartan
(Avapro)
Losartan (Cozaar,
Hyzaar)
Olmesartan
(Benicar)
Telmisartan
(Micardis)
Valsartan
(Diovan)

Lisinopril
(Prinivil/Zestril)
Moexipril
(Univasc)
Perindopril
(Aceon)
Quinapril
(Accupril)
Ramipril
(Altace)
Trandolapril
(Mavik)

AA

Eplerenone
(Inspra)
Spironolactone
(Aldactone)

Adapted from American College of Cardiology, n.d..; Ogbru, 2016a, 2016b, 2016c.

Data Analysis
The researcher used the Statistical Package for the Social Science (SPSS)
software version 23 to analyze the collected data. Statistical analysis of the data helped
the researcher answer the study’s research questions by (a) determining the extent to
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which select Mississippi hospitals adhering to evidence-based pharmacological
management guidelines for management of congestive heart failure, and (b) determining
the relationship between adherence to guidelines for pharmacologic management of heart
failure and readmission to hospital for select Mississippi hospitals.
First, the researcher utilized descriptive statistics to analyze the patient’s
demographic data. Examples of descriptive statistics used in this study are the measures
of central tendency and frequency distribution. Mean was the primary measure of central
tendency used in this study. The measures of central tendency provide an overall
description of the sample’s average age, gender, and race (LoBiondo-Wood & Haber,
2010, pp. 314-315). The frequency distribution displays the number of times (and
percentage) each of the pharmacological classes was noted in the patients’ medication list
at the index admission and discharge and readmission.
The researcher also utilized inferential statistics to analyze the collected data.
Inferential statistical analysis helped the researcher determine if there is a relationship or
difference between variables. Research question one and two analysis consisted of a ttest and independent samples t-test. In this study, the researcher is trying to determine
whether the utilization of evidence-based heart failure pharmacologic guidelines have an
impact on heart failure readmissions.
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CHAPTER IV – DATA ANALYSIS
Introduction
The purpose of this study was to explore the relationship of adherence to
evidence-based guidelines for pharmacologic management by selected Mississippi
hospitals and their hospital readmission rates. Chapter II discussed the literature
supporting adherence to evidence-based guidelines and the impact it had on readmissions.
Chapter III discussed the methods used to collect data and introduced the statistics that
would be used with the Statistical Package for the Social Science to analyze the data.
Chapter IV presents the results of data analysis. The unit of analysis for this study was
the re-hospitalizations of the heart failure patients.
Description of the Sample
A total of 31 charts were available for review. The limited number of charts was
due to lack of chart availability and limited staff available to pull additional charts.
Descriptive statistics were generated to describe patients whose records were included in
the analyses. The mean age of patients at admission was 77.7(SD = 11.3) years.
Frequencies were generated to describe the sex and race of the patients. The study
included 15 females and 16 males. The study consisted of 24 Caucasians, 6 African
Americans, and 1 American Indian.
Clinical Data
Frequencies and percentages were generated to describe the admitting diagnoses
based on ICD-9 codes or presentation of symptoms discussed in chapter I and III. Only 6
(19.4%) of the patients in the study had an ICD-9 code documentation of heart failure.
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The other 25 (80.6%) patients had a confirmed diagnosis of heart failure by physician
documentation.
All of the patients (N = 31) in this study were identified as having stage C heart
failure, or as having the presence of heart disease while exhibiting the symptoms of heart
failure. Means and standard deviations were generated to describe the weight in
kilograms, the height in inches, blood pressure (mmHg), and pulse. The mean height was
67.65 (SD = 3.77) inches and the mean weight was 89.23 (SD = 26.40) kilograms.
The review of vital signs is an integral factor in the management of heart failure
because they help to determine whether the patient’s hypertension is adequately
controlled. Uncontrolled hypertension is one of the risk factors for heart failure as well
as one of the factors that can lead to worsening heart failure (Dumitru & Baker, 2016).
The mean systolic blood pressure upon admission was 140.45 (SD = 33.48). The
mean diastolic blood pressure upon admission was 69.34 (SD = 20.54). The mean pulse
upon admission was 83.77 (SD = 22.58). The mean systolic blood pressure upon
discharge was 133.32 (SD = 20.11). The mean diastolic blood pressure upon discharge
was 67.39 (SD = 13.88). The mean pulse upon discharge was 72. 90 (SD = 15.90). The
results are presented in Table 4.
The frequency of lab values upon admission and discharge were analyzed to
assess an overview of the patients' labs present at admission and discharge. The review
of lab values is pertinent in the treatment of heart failure because they help to monitor
whether other vital organs, such as the kidneys, are being affected (AHA, 2016). The
review of lab values is also important because they relate to whether a patient’s comorbid
conditions are under control, which also has an influence on readmissions. If a patient’s
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comorbid conditions are not adequately controlled, then that can influence the patient’s
heart failure disease and thus increase the chance of readmission.
The labs analyzed were BUN, creatinine, BNP, potassium, HgA1C, and
hemoglobin. BUN and creatinine are labs used to monitor kidney function (Table 3).
The kidney function of heart failure patients is especially important because some heart
failure medications can alter their renal function (Konstam, 2011; Metra, Cotter,
Gheorghiade, Cas, & Voors, 2012).
BNP is a significant lab when treating heart failure because it measures how the
heart is functioning (Doust, Lehman, & Glasziou, 2006). Potassium is an important lab
to measure because some heart failure medications predispose patients to hyperkalemia.
HgA1C is a lab used to monitor whether a diabetic patient's blood sugar levels are
adequately controlled. Diabetes can predispose a patient to diabetes as well as worsen
heart failure in those affected by the disease (Cas et al., 2015). Finally, it is important to
monitor the hemoglobin levels of heart failure patients because they are at an increased
risk for anemia especially when the patient has kidney disease (Anand, 2008; Tang &
Katz, 2006). The analysis of admitting lab values is presented in Table 4.
Table 4
Lab Values

BUN
Creatinine
BNP
Potassium
HgA1C
HgB

N

Mean (SD)

31
31
30
30
31
31

43.23 (29.28)
2.27 (1.20)
858.03 (757.98)
4.39 (0.69)
89.99 (27.98)
10.52 (2.51)
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The frequency of the comorbid conditions among the patients was also analyzed.
Many heart failure patients have other comorbid conditions that either predisposed them
to heart failure or occurred as a result of the disease. Healthcare professionals have to
concurrently treat the patient’s heart failure as well as the comorbid condition(s) to
decrease the worsening of the disease. The lack of inclusion of a variety of comorbid
conditions in the study of heart failure has been cited as a potential limitation in the
sufficient management of the disease (Yancy et al., 2013, p. e299).
The insufficient inclusion and treatment of comorbid conditions falls under the
umbrella of non-adherence when considering the utilization of evidence-based
pharmacological guidelines. The guidelines cannot be properly adhered to if the patient’s
other comorbid conditions are not adequately managed. As stated, some of the patient’s
comorbid conditions can either predispose them to heart failure if not managed
appropriately or can contribute to worsening of the disease. The analysis of comorbid
conditions is presented in Table 5.
Smoking status and insurance status of the patients were also analyzed using
measures of central tendency. The smoking status of these patients are important to
determine whether they were self-promoting a better lifestyle. Current smoking statuses
have been associated with worsening disease and a decrease in quality of life (Conard,
Haddock, Poston, & Spertus, 2009). Three patients (9.7%) were current smokers, 15 of
the patients (48.4%) had never smoked, 11 patients (35.5%) were past smokers, and data
was not available for 2 of the patients in the study. The insurances were examined to
determine whether they might have an influence on the pharmacological treatments
received. The majority of the patients in the study (71.0%) had only Medicare along with
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a supplementary private insurance (53.1%). The results of the study showed that 25.8%
of the patients had Medicare and Medicaid. Only one patient was identified as being noninsured.
Table 5
Comorbid Conditions
N

%

Comorbid ConditionsVariables
Diabetes

Yes
No

18
13

58.1
41.9

Hypertension

Yes
No

24
7

77.4
22.6

Ischemic Heart Disease

Yes
No

16
15

51.6
48.4

Hyperlipidemia

Yes
No

11
20

35.5
64.5

Anemia

Yes
No

12
19

38.7
61.3

Chronic Kidney Disease

Yes
No

19
12

61.3
38.7

COPD

Yes
No

10
21

32.3
67.7

Atrial Fibrillation

Yes
No

14
17

45.2
54.8

Myocardial Infarction

Yes
No

6
25

19.4
80.6
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Research question #1 - To what extent are select Mississippi hospitals adhering to
evidence-based pharmacological management guidelines for management of heart
failure?
The researcher analyzed the frequency of utilization of each pharmacological
class upon index admission/discharge and readmission/discharge to answer question one.
The results of the analysis indicated that BBs were the most commonly used
pharmacological treatments in the management of heart failure. Patients were either
prescribed the medication or had sufficient documentation contraindicating the utilization
of the medication in their pharmacological management. The frequency of BBs (83.9%)
remained the same upon admission/discharge and readmissions/discharge
Table 6
Frequency of Medication Adherence and Non-Adherence
Medication
class

Index Admission and Discharge
Yes
No

ACE Inhibitor

13 (41.9%)

18 (58.1%)

8 (25.8%)

23 (74.2%)

Beta blocker

26 (83.9%)

5 (16.1%)

26 (83.9%)

5 (16.1%)

Angiotensin
receptor
blocker

10 (32.3%)

21 (67.7%)

7 (22.6%)

24 (77.4%)

Aldosterone
inhibitor

8 (25.8%)

23 (74.2%)

10 (32.3%)

21 (67.7%)

Yes

Readmission
No

Research question #2 - What is the relationship between adherence to guidelines
for pharmacologic management of heart failure and readmission to select Mississippi
hospitals?
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The relationship between adherence to guidelines for pharmacological
management and readmission was first examined by examining distribution of
readmissions based on days since index admission (see Table 7). The first column
represents the number of days since admission the patients were readmitted, and the
second column represents the frequency of patients who readmitted on the number of
days since admission.
Table 7
Frequency of Readmission Since Discharge

Valid

1
3
6
7
8
9
11
12
14
17
22
23
24
26
28
29
30
32
34
36
42
Total

Frequency
2
2
1
3
1
1
1
2
1
3
1
1
2
1
1
1
3
1
1
1
1
31

Percent
6.3
6.3
3.1
9.4
3.1
3.1
3.1
6.3
3.1
9.4
3.1
3.1
6.3
3.1
3.1
3.1
9.4
3.1
3.1
3.1
3.1
96.9

Valid Percent
6.5
6.5
3.2
9.7
3.2
3.2
3.2
6.5
3.2
9.7
3.2
3.2
6.5
3.2
3.2
3.2
9.7
3.2
3.2
3.2
3.2
100.0

Cumulative Percent
6.5
12.9
16.1
25.8
29.0
32.3
35.5
41.9
45.2
54.8
58.1
61.3
67.7
71.0
74.2
77.4
87.1
90.3
93.5
96.8
100.0

Next, a t-test was performed to analyze if there was a difference in the means
between the adherence and non-adherence of the four pharmacological classes. Lastly,
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the relationship between adherence to guidelines for pharmacological management and
readmission was examined using an independent samples t-test looking for a significance
level of .05. Each pharmacological class of medication was examined.
There was no significant difference in the scores for ACEI utilization or
documentation (M = 18.92, SD = 9.691) and no ACEI utilization or documentation (M =
17.56, SD = 13.053); t (29) = -.319, p = .752. There was no significant difference in the
scores for ACEI2 utilization or documentation (M = 21.00, SD = 11.514) and no ACEI2
utilization or documentation (M = 17.13, SD = 11.718); t (29) = -.808, p = .426. There
was no significant difference in the scores for BB utilization or documentation (M =
19.12, SD = 11.810) and no BB utilization or documentation (M = 13.00, SD = 9.925); t
(29) = -1.803, p = .288. There was no significant difference in the scores for BB2
utilization or documentation (M = 19.12, SD = 11.810) and no BB2 utilization or
documentation (M = 13.00, SD = 9.925); t (29) = -1.803, p = .288. There was no
significant difference in the scores for ARB utilization or documentation (M = 16.80, SD
= 10.465) and no ARB utilization or documentation (M = 18.76, SD = 12.300); t (29) =
.434, p = .667. There was no significant difference in the scores for ARB2 utilization or
documentation (M = 14.29, SD = 12.216) and no ARB2 utilization or documentation (M
= 19.25, SD = 11.437); t (29) = .996, p = .327. There was no significant difference in AA
utilization or documentation (M = 17.38, SD = 14.667) and no AA utilization or
documentation (M = 18.39, SD = 10. 714); t (29) = .210, p = .835. There was no
significant difference in AA2 utilization or documentation (M = 17.60, SD = 13.954) and
no AA2 utilization or documentation (M = 18.38, SD = 10,679); t (29) = .172, p = .864.
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The results of the study indicated no significant relationship between
pharmacological management and readmission. This may be due in part to the limited
amount of data for analysis. The results suggested a potential difference in readmission
with the utilization of ACEI or BB, but that impact can only be determined by an analysis
of more data. The results are presented in Tables 8 and 9. The standard abbreviation for
each pharmacological class is used to represent the utilization of that pharmacological
class at the index admission/discharge. This is followed by the standard abbreviation
with the number 2 to represent utilization of that pharmacological class at readmission
Table 8
Multiple T-Test Results
N
ACEI

Non-adherent
Adherent

18
13

Mean (SD) number of days between
discharge and readmission (time)
17.56 (13.05)
18.92 (9.69)

ACEI2

Non-adherent
Adherent

23
8

17.13 (11.72)
21.00 (11.51)

BB

Non-adherent
adherent

5
26

13.00 (9.93)
19.12 (11.81)

BB2

Non-adherent
Adherent

5
26

13.00 (9.93)
19.12 (11.81)

ARB

Non-adherent
Adherent

21
10

18.76 (12.30)
16.80 (10.47)

ARB2

Non-adherent
Adherent

24
7

19.25 (11.44)
14.29 (12.22)

AA

Non-adherent
Adherent

23
8

18.39 (10.71)
17.38 (14.67)

AA2

Non-adherent
Adherent

21
10

18.38 (10.68)
1.
(13.95)
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Table 9
Multiple Independent T-Test Results
Variables

Groups (n)

Mean (SD)
number of days
between
discharge and
readmission
(time)

Test
Statistic
(p-value)

95% C.I.

LL
-10.316

UL
7.401

ACEI

Non-adherent (18)
Adherent
(13)

17.56 (13.05)
18.92 (9.69)

-0.319
(0.752)

ACEI2

Non-adherent (23)
Adherent
(8)

17.13 (11.72)
21.00 (11.51)

-0.808
(0.426)

-13.665

5.926

BB

Non-adherent (5)
Adherent
(26)

13.00 (9.93)
19.12 (11.81)

-1.083
(0.288)

-17.669

5.438

BB2

Non-adherent (5)
Adherent
(26)

13.00 (9.93)
19.12 (11.81)

-1.083
(0.288)

-17.669

5.438

ARB

Non-adherent (21)
Adherent
(10)

18.76 (12.30)
16.80 (10.47)

0.434
(0.667)

-7.280

11.204

ARB2

Non-adherent (24)
Adherent
(7)

19.25 (11.44)
14.29 (12.22)

0.996
(0.327)

-5.229

15.158

AA

Non-adherent (23)
Adherent
(8)

18.39 (10.71)
17.38 (14.67)

0.210
(0.835)

-8.882

10.914

AA2

Non-adherent (21)
Adherent
(10)

18.38 (10.68)
17.60 (13.95)

0.172
(0.864)

-8.486

10.048

Summary
This chapter presented the results of the data analysis. Data results revealed that
the majority of these patients had more than one comorbid condition, along with their
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primary diagnosis of heart failure. The data results did show that patients frequently
readmit to the hospital within 30 days of discharge; however, the results did not illustrate
a significant relationship between evidence-based pharmacological therapy and
readmission. This may be due to the lack of data. Beta blockers were the most
commonly used medication upon admission/discharge and readmission/discharge. The
results also showed that some of the pharmacological classes of medications were not
utilized, or there was not sufficient documentation explaining why they were not being
used. The next chapter will discuss the conclusions and findings of this study,
limitations, and recommendations for future research.

53

CHAPTER V – CONCLUSIONS, FINDINGS, AND RECOMMENDATIONS
FOR FUTURE RESEARCH
Introduction
The purpose of this study was to explore the adherence to evidence-based
guidelines for pharmacologic management by select Mississippi hospitals and their
hospital readmission rates. This was examined by determining to what extent select
Mississippi hospitals adhere to evidence-based pharmacological management guidelines
for the management of heart failure and by determining the relationship between
adherence to guidelines for pharmacologic management of heart failure and readmission
to hospital for select Mississippi hospitals. Chapter V will highlight the study’s
conclusions, findings, limitations, and recommendations for future research on this topic.
Conclusion
The researcher can conclude that the study successfully answered question one;
however, question two would require additional data for analysis to determine if there is
indeed a significance.
Findings
The overall findings of this study indicated there was no relationship between
adherence to evidence-based guidelines for pharmacologic management and
readmissions. The first question addressed was: “To what extent are select Mississippi
hospitals adhering to evidence-based pharmacological management guidelines for
management of heart failure?” Data was collected on a total of 31 patients. The
researcher searched the charts to examine the frequency of utilization of the four main
pharmacological classes upon admission or discharge. If the medication was not utilized,
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the researcher went to the next step of searching for specific documentation
contraindicating the use of the medication in the patients’ pharmacologic management.
A frequency analysis was used to statistically analyze the extent to which
evidence-based guidelines were being adhered to. The results indicated that evidencebased pharmacological medications were either not frequently prescribed or did not have
sufficient documentation supporting or contraindicating the utilization of the medication
in the patients’ pharmacological management. BBs were the only medications identified
as being prescribed frequently.
The second research question addressed was: “What is the relationship between
adherence to guidelines for pharmacologic management of heart failure and readmission
to hospital for select Mississippi hospitals?” First, a t-test was performed to analyze if
there was a difference in the mean number of days between adherence and non-adherence
of the four pharmacological classes. The results of this test allowed the researcher to
determine whether the adherence or non-adherence to each pharmacological class
contributed to an increase or decrease in the mean number of days the patients stayed out
of the hospital since discharge. An increase in mean number of days in the non-adherent
group would indicate not adhering to the pharmacological class was associated keeping
patients out of the hospital longer. A decrease in mean number of days in the nonadherent group would indicate not adhering to the pharmacological class was not
associated with keeping patients out of the hospital longer.
A similar rationale was applied to the relationship between adherence of
pharmacological classes and time. An increase in mean number of days in the adherent
group would indicate adhering to the pharmacological class was associated with keeping
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patients out of the hospital longer. A decrease in mean number of days in the adherent
group would indicate adhering to the pharmacological class was not associated with
keeping patients out of the hospital longer.
According to the results of the t-tests, there was not significant difference in time
among the pharmacological classes. For example, the patients in the ACEI non-adherent
group stayed out of the hospital 17 days before being readmitted. There was not a major
difference in the ACEI adherent group because the patients in that group stayed out of the
hospital only 18 days before being readmitted. Similar results were seen among the other
pharmacological classes. These results indicated to the researcher there was not a
relationship between adhering to the pharmacological classes and readmission.
An independent samples t-test was then used to statistically analyze the
relationship between adherence to guidelines for pharmacological management and
readmission. The results of the study indicated there was not a significant relationship
between pharmacological management and readmission. This may be due in part to the
limited amount of data for analysis.
Recommendations for Future Research
The utilization of evidence-based interventions is an essential part of quality
patient care. Future research of this topic should include a larger sample to determine
whether there is any significance between the utilization of evidence-based
pharmacologic medications and readmissions. This study was limited to a total of 31
charts, which was due to chart availability and the limited number of staff available to
pull more charts. Future studies should also include the incorporation of the patients’
comorbid conditions because they also have a significant influence on patient care and
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their regimen of medications. Yancy et al. (2013) made reference to the inclusion of
comorbid conditions in future studies in their research gaps and recommendations for
future research. Several of the studies the authors reviewed excluded patients with
conditions limiting their recommendations for these patients (p. e299).
Qualitative studies on this topic would also prove beneficial. Qualitative studies
would offer insight from the patients’ perspectives on what influences their decision to
readmit to the hospital and whether their compliance to their medication regimen
influences readmission. Qualitative studies would also offer information on whether
patients have a thorough understanding of their disease and the necessary steps to
effectively manage it.
Another recommendation would be to use the data collected from this study as a
measure of quality assurance in the healthcare facility. This study can be utilized by the
staff of the healthcare facility in which the data was collected to measure and improve
quality care in the healthcare facility. The data collected from this study could be used
specifically as a learning tool to guide healthcare staff about the importance of evidencebased practice and the basis of incorporating evidence-based practice into patient care.
There are also implications for nurses and physicians. While conducting the chart
reviews, it was noted that there was not sufficient documentation contraindicating the
utilization of evidence-based medications in the patient’s care. Healthcare personnel are
aware of the importance of documentation; however, sometimes it is important to remind
them of the necessity of sufficient documentation. Documentation is an essential part of
continuity of care and can also be the difference between saving a person’s life. All
healthcare members involved in patient care refer to documentation many times before
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decisions are made. Nurses are especially aware of the importance of documentation
because they are often taught that if a situation is not documented, then that situation did
not occur. Thus, sufficient documentation can be the turning point in legal cases
concerning patient care.
Summary
This study explored the adherence to evidence-based guidelines for
pharmacologic management by select Mississippi hospitals and the potential impact it
had on their hospital readmission rates. This was achieved by first determining to what
extent a select Mississippi hospital adhered to evidence-based pharmacological
management guidelines for the management of heart failure and second by determining
the impact adherence to those guidelines had on readmission rates. The results of the
study did show a potential impact between adherence to guidelines and readmission rates;
however, the results were limited to a potential impact due to the limited amount of data
available for data analysis. The study did, however, demonstrate the importance of
incorporating evidence-based guidelines into the care patients receive and the importance
of thorough documentation.
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APPENDIX A – Data Abstraction Tool
Date Data Collected _____________
Date Data Entered _____________
TITLE
KERI A. BARRON, MSN, RN
DATA COLLECTION FORM
1. Subject ID Number

__________________

2. Subject medical record number

__________________

DEMOGRAPHIC DATA
3. Age: ________
4. Gender:
Female

__________________

Male

__________________

5. Race/Ethnicity
Caucasian/White

__________________

African American/Black

__________________

Hispanic/Latino

__________________

Asian American/Pacific Islander

__________________

American Indian

__________________
CLINICAL DATA

6. Admission date

__________________

7. Discharge date

__________________

8. ICD-9 Code

__________________

9. Stage of Heart Failure
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A

__________________

B

__________________

C

__________________

D

__________________

10. Height

__________________

11. Weight

__________________

12. Comorbid Conditions:
Diabetes

__________________

Hypertension

__________________

Ischemic Heart Disease

__________________

Hyperlipidemia

__________________

Anemia

__________________

Chronic Kidney Disease

__________________

COPD

__________________

Atrial Fibrillation

__________________

Myocardial Infarction

__________________

13. Laboratory Values – Obtained at Admission
Blood Urea Nitrogen (BUN) (10-20)

__________________

Creatinine (0.7-1.3)

__________________

Brain Natriuretic Peptide (BNP) (

__________________

Potassium (3.5 – 5.0)

__________________

HgA1c (if diabetic) (3.9 – 6.9)

__________________

Hemoglobin (13.5 – 17.5)

__________________
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14. Vital Signs at Admission
BP

__________________

P

__________________

15. Vital Signs at Discharge
BP

__________________

P

__________________

16. Smoking Status
Never Smoked

__________________

Current Smoker

__________________

Past Smoker

__________________

17. Pharmacological Heart Failure Treatment on Admission/Discharge
Angiotensin-converting enzyme inhibitors (Yes or No)

__________________

If no, documentation of reason why
____________________________________________________________
____________________________________________________________
____________________________________________________________
Beta blockers (Yes or No)

__________________

If no, documentation of reason why
____________________________________________________________
____________________________________________________________
____________________________________________________________
Angiotensin receptor blockers (Yes or No)
If no, documentation of reason why
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__________________

____________________________________________________________
____________________________________________________________
____________________________________________________________
Aldosterone receptor antagonist (Yes or No)

__________________

If no, documentation of reason why
____________________________________________________________
____________________________________________________________
____________________________________________________________
18. Pharmacological Heart Failure Treatment on Readmission
Readmission date

__________________

Angiotensin-converting enzyme inhibitors (Yes or No)

__________________

If no, documentation of reason why
____________________________________________________________
____________________________________________________________
____________________________________________________________
Beta blockers (Yes or No)

__________________

If no, documentation of reason why
____________________________________________________________
____________________________________________________________
____________________________________________________________
Angiotensin receptor blockers (Yes or No)

__________________

If no, documentation of reason why
____________________________________________________________
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____________________________________________________________
____________________________________________________________
Aldosterone receptor antagonist (Yes or No)

__________________

If no, documentation of reason why
____________________________________________________________
____________________________________________________________
____________________________________________________________
19. Insurance Provider
Medicare

__________________

Medicaid

__________________

Medicare/Medicaid

__________________

Private Insurance

__________________

Non – Insured

__________________
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